Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 28 Feb 2018 |
| Genmab 2017 Annual Report | 21 Feb 2018 |
| Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab) | 23 Jan 2018 |
| U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma | 19 Jan 2018 |